Compare Orchid Chemicals with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DR. REDDYS LAB - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DR. REDDYS LAB ORCHID PHARMA LTD/
DR. REDDYS LAB
 
P/E (TTM) x -0.5 17.4 - View Chart
P/BV x 0.1 3.3 3.5% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ORCHID PHARMA LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DR. REDDYS LAB
Mar-19
ORCHID PHARMA LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1942,875 6.7%   
Low Rs351,888 1.9%   
Sales per share (Unadj.) Rs276.5930.2 29.7%  
Earnings per share (Unadj.) Rs-79.2117.4 -67.5%  
Cash flow per share (Unadj.) Rs-43.5185.8 -23.4%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs53.9844.4 6.4%  
Shares outstanding (eoy) m70.45166.07 42.4%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.42.6 16.2%   
Avg P/E ratio x-1.420.3 -7.1%  
P/CF ratio (eoy) x-2.612.8 -20.6%  
Price / Book Value ratio x2.12.8 75.3%  
Dividend payout %017.0 0.0%   
Avg Mkt Cap Rs m8,067395,496 2.0%   
No. of employees `0002.822.0 12.7%   
Total wages/salary Rs m2,52733,562 7.5%   
Avg. sales/employee Rs Th6,956.17,032.8 98.9%   
Avg. wages/employee Rs Th902.51,527.9 59.1%   
Avg. net profit/employee Rs Th-1,993.0887.7 -224.5%   
INCOME DATA
Net Sales Rs m19,477154,482 12.6%  
Other income Rs m4073,375 12.1%   
Total revenues Rs m19,884157,857 12.6%   
Gross profit Rs m1,10331,782 3.5%  
Depreciation Rs m2,51911,348 22.2%   
Interest Rs m5,227889 587.9%   
Profit before tax Rs m-6,23622,920 -27.2%   
Minority Interest Rs m200-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1253,858 -3.2%   
Profit after tax Rs m-5,58019,500 -28.6%  
Gross profit margin %5.720.6 27.5%  
Effective tax rate %2.016.8 11.9%   
Net profit margin %-28.712.6 -227.0%  
BALANCE SHEET DATA
Current assets Rs m11,014111,101 9.9%   
Current liabilities Rs m32,06058,973 54.4%   
Net working cap to sales %-108.133.7 -320.2%  
Current ratio x0.31.9 18.2%  
Inventory Days Days9579 119.6%  
Debtors Days Days3494 35.6%  
Net fixed assets Rs m29,440101,245 29.1%   
Share capital Rs m705830 84.9%   
"Free" reserves Rs m2,043139,406 1.5%   
Net worth Rs m3,800140,236 2.7%   
Long term debt Rs m9,01822,000 41.0%   
Total assets Rs m46,510224,656 20.7%  
Interest coverage x-0.226.8 -0.7%   
Debt to equity ratio x2.40.2 1,512.8%  
Sales to assets ratio x0.40.7 60.9%   
Return on assets %-0.89.1 -8.4%  
Return on equity %-146.913.9 -1,056.1%  
Return on capital %-3.714.9 -25.0%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51388,673 8.5%   
Fx outflow Rs m5,64919,104 29.6%   
Net fx Rs m1,86569,569 2.7%   
CASH FLOW
From Operations Rs m1,68228,704 5.9%  
From Investments Rs m-9,860-7,727 127.6%  
From Financial Activity Rs m6,644-21,326 -31.2%  
Net Cashflow Rs m-1,535-314 488.9%  

Share Holding

Indian Promoters % 32.3 25.5 126.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 5.4 85.2%  
FIIs % 3.3 35.3 9.3%  
ADR/GDR % 4.6 18.5 24.9%  
Free float % 55.3 15.3 361.4%  
Shareholders   84,811 75,885 111.8%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Auto Sector Sales in October, Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

On Monday, Indian share markets witnessed buying interest during closing hours and ended their day marginally higher.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS